Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
J Clin Oncol
    June 2026
  1. SHARMA MR, Powderly J, Kuboki Y, Strickler JH, et al
    Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
    J Clin Oncol. 2026 Jun 15:JCO2601401. doi: 10.1200/JCO-26-01401.
    >> Share

  2. QI C, Liu C, Gong J, Wang X, et al
    Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.
    J Clin Oncol. 2026 Jun 4:JCO2501090. doi: 10.1200/JCO-25-01090.
    >> Share

  3. DE LA FOUCHARDIERE C, Zaanan A, de Montfort A, Cohen R, et al
    Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.
    J Clin Oncol. 2026;44:1520-1528.
    >> Share

    May 2026
  4. CHAN KK, Chu RW, Cheung MC, Courneya KS, et al
    Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial.
    J Clin Oncol. 2026 May 31:101200JCO2600765. doi: 10.1200/JCO-26-00765.
    >> Share

  5. BROWN TJ, Ozer M, Grewal US, Hornstein NJ, et al
    Has Colorectal Cancer (c-)Met Its Match With Telisotuzumab Adizutecan?
    J Clin Oncol. 2026 May 27:JCO2600753. doi: 10.1200/JCO-26-00753.
    >> Share

  6. SINICROPE FA, Segovia D, Sharma N, Alberts SR, et al
    Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).
    J Clin Oncol. 2026;44:1401-1415.
    >> Share

  7. GOGENUR I, Justesen TF, Tarpgaard LS, Bulut M, et al
    Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial.
    J Clin Oncol. 2026 May 5:JCO2502274. doi: 10.1200/JCO-25-02274.
    >> Share

  8. SHARMA MR, Powderly J, Kuboki Y, Strickler JH, et al
    Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
    J Clin Oncol. 2026 May 1:JCO2501525. doi: 10.1200/JCO-25-01525.
    >> Share

    April 2026
  9. GELLI M, Ewald J, Tanguy ML, Passot G, et al
    Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.
    J Clin Oncol. 2026 Apr 22:JCO2501737. doi: 10.1200/JCO-25-01737.
    >> Share

  10. OBERSTEIN PE, Hecht JR, Raghav K, Pietrantonio F, et al
    Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
    J Clin Oncol. 2026 Apr 21:JCO2502187. doi: 10.1200/JCO-25-02187.
    >> Share

  11. WU YL, Manji GA
    Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time?
    J Clin Oncol. 2026 Apr 16:JCO2600369. doi: 10.1200/JCO-26-00369.
    >> Share

  12. NOIRET B, Perez RO, Conroy T, Brown CJ, et al
    Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.
    J Clin Oncol. 2026;44:1016-1027.
    >> Share

  13. MEI WJ, Wang XZ, Zhang X, Sun YM, et al
    Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial.
    J Clin Oncol. 2026;44:970-980.
    >> Share

    March 2026
  14. OWENS CA, Ludmir EB, Liu Q, Qiu W, et al
    Reply to: Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer.
    J Clin Oncol. 2026 Mar 11:JCO2600051. doi: 10.1200/JCO-26-00051.
    >> Share

  15. LIU Y, Liu Y, Wei Y
    Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer.
    J Clin Oncol. 2026 Mar 11:JCO2502569. doi: 10.1200/JCO-25-02569.
    >> Share

  16. LIU T, Luo S, Yuan X, Liu D, et al
    Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
    J Clin Oncol. 2026 Mar 4:JCO2500716. doi: 10.1200/JCO-25-00716.
    >> Share

    February 2026
  17. MORRIS VK, Ciombor KK, Xiao L, Ochieng JK, et al
    NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
    J Clin Oncol. 2026;44:497-507.
    >> Share

    January 2026
  18. ZWANENBURG ES, El Klaver C, Wisselink DD, Punt CJA, et al
    Erratum: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial.
    J Clin Oncol. 2026 Jan 29:JCO2600094. doi: 10.1200/JCO-26-00094.
    >> Share

  19. KANEMITSU Y, Shimizu Y, Mizusawa J, Inaba Y, et al
    Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.
    J Clin Oncol. 2026 Jan 21:JCO2501231. doi: 10.1200/JCO-25-01231.
    >> Share

  20. GERMANI MM, Borelli B, Cremolini C
    Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer.
    J Clin Oncol. 2026 Jan 20:JCO2502817. doi: 10.1200/JCO-25-02817.
    >> Share

  21. LIANG X, Lei H
    From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer.
    J Clin Oncol. 2026 Jan 20:JCO2502335. doi: 10.1200/JCO-25-02335.
    >> Share

  22. IVESON T, Saunders MP, Kelly C, Kerr RS, et al
    Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.
    J Clin Oncol. 2026 Jan 9:JCO2500621. doi: 10.1200/JCO-25-00621.
    >> Share

  23. CONCA V, Rossini D, Antoniotti C, Lonardi S, et al
    Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.
    J Clin Oncol. 2026 Jan 8:JCO2501337. doi: 10.1200/JCO-25-01337.
    >> Share

    December 2025
  24. YEH JM, Seguin CL, Stratton KL, Leisenring WM, et al
    Benefits, Harms, and Burden of Colorectal Cancer Screening Among Childhood Cancer Survivors Previously Treated With Abdominopelvic Radiation.
    J Clin Oncol. 2025 Dec 17:JCO2500661. doi: 10.1200/JCO-25-00661.
    >> Share

  25. RATAIN MJ, Fojo AT
    Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer.
    J Clin Oncol. 2025 Dec 5:JCO2501607. doi: 10.1200/JCO-25-01607.
    >> Share

    November 2025
  26. STAHLER A, Modest DP, Stintzing S, Borelli B, et al
    Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
    J Clin Oncol. 2025 Nov 18:JCO2500596. doi: 10.1200/JCO-25-00596.
    >> Share

  27. OWENS CA, Ludmir EB, Liu Q, Qiu W, et al
    Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report.
    J Clin Oncol. 2025;43:3403-3421.
    >> Share

    October 2025
  28. ASSENAT E, Ben Abdelghani M, Gourgou S, Perrier H, et al
    Erratum: Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.
    J Clin Oncol. 2025 Oct 28:JCO2502239. doi: 10.1200/JCO-25-02239.
    >> Share

  29. LIN JK, Niu J, Giordano SH, Li P, et al
    Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
    J Clin Oncol. 2025;43:3254-3265.
    >> Share

  30. CHEN L, Wang Y, Cai C, Ding Y, et al
    Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
    J Clin Oncol. 2025 Oct 2:JCO2502281. doi: 10.1200/JCO-25-02281.
    >> Share

    September 2025
  31. BEITER ER, Patel SR, Chen CT
    Immunotherapy Efficacy in Mismatch Repair-Proficient Colorectal Cancer Patients With and Without Liver Metastases.
    J Clin Oncol. 2025 Sep 11:JCO2501044. doi: 10.1200/JCO-25-01044.
    >> Share

  32. GERMANI MM, Borelli B, Hashimoto T, Nakamura Y, et al
    Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
    J Clin Oncol. 2025 Sep 4:JCO2501003. doi: 10.1200/JCO-25-01003.
    >> Share

    July 2025
  33. WANKHEDE D, Halama N, Kloor M, Brenner H, et al
    Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status.
    J Clin Oncol. 2025 Jul 14:JCO2500148. doi: 10.1200/JCO-25-00148.
    >> Share

    June 2025
  34. ASSENAT E, Ben Abdelghani M, Gourgou S, Perrier H, et al
    Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.
    J Clin Oncol. 2025 Jun 20:JCO2402754. doi: 10.1200/JCO-24-02754.
    >> Share

    May 2025
  35. SHAH P, Philip T
    They Not Like Us: Evaluating the Diverse Strategies in Locally Advanced Rectal Cancer Treatment.
    J Clin Oncol. 2025;43:1620-1624.
    >> Share

  36. BACHET JB, de Gramont A, Raeisi M, Rakez M, et al
    Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancerologie Digestive Database.
    J Clin Oncol. 2025 May 5:JCO2401968. doi: 10.1200/JCO-24-01968.
    >> Share

  37. VEENSTRA CM, Abrahamse P, Hamilton AS, Ward KC, et al
    Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2.
    J Clin Oncol. 2025;43:1587-1596.
    >> Share

    April 2025
  38. ROUSSEAU B, Cercek A
    Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer.
    J Clin Oncol. 2025 Apr 11:JCO2500205. doi: 10.1200/JCO-25-00205.
    >> Share

  39. PIETRANTONIO F, Salvatore L, Esaki T, Modest DP, et al
    Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
    J Clin Oncol. 2025 Apr 11:JCO2402026. doi: 10.1200/JCO-24-02026.
    >> Share

    February 2025
  40. ZHANG J, Chi P, Shi L, Cui L, et al
    Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years.
    J Clin Oncol. 2025;43:633-640.
    >> Share

  41. WIDMAR M, McCain M, Mishra Meza A, Ternent C, et al
    Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma Trial.
    J Clin Oncol. 2025;43:672-681.
    >> Share

  42. MORRIS VK, Kennedy EB, Amin MA, Aranha O, et al
    Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
    J Clin Oncol. 2025;43:605-615.
    >> Share

  43. TAIEB J, Souglakos J, Boukovinas I, Falcoz A, et al
    Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.
    J Clin Oncol. 2025 Feb 4:JCO2400648. doi: 10.1200/JCO.24.00648.
    >> Share

  44. STINTZING S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, et al
    Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
    J Clin Oncol. 2025 Feb 4:JCO2401174. doi: 10.1200/JCO.24.01174.
    >> Share

    January 2025
  45. GALLOIS C, Sroussi M, Andre T, Mouillet-Richard S, et al
    Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials.
    J Clin Oncol. 2025 Jan 31:JCO2302262. doi: 10.1200/JCO.23.02262.
    >> Share

  46. OULADAN S, Orouji E
    Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.
    J Clin Oncol. 2025 Jan 13:JCO2402081. doi: 10.1200/JCO-24-02081.
    >> Share

  47. RAGHAV KPS, Guthrie KA, Tan B Jr, Denlinger CS, et al
    Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
    J Clin Oncol. 2025 Jan 6:JCO2401710. doi: 10.1200/JCO-24-01710.
    >> Share

    November 2024
  48. AVALLONE A, Giuliani F, De Stefano A, Santabarbara G, et al
    Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial.
    J Clin Oncol. 2024 Nov 22:JCO2400979. doi: 10.1200/JCO.24.00979.
    >> Share


  49. Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
    J Clin Oncol. 2024 Nov 19:JCO2402458. doi: 10.1200/JCO-24-02458.
    >> Share

    October 2024
  50. AHN DH, Ridinger M, Cannon TL, Mendelsohn L, et al
    Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
    J Clin Oncol. 2024 Oct 30:JCO2401266. doi: 10.1200/JCO-24-01266.
    >> Share

  51. SCOTT AJ, Kennedy EB, Berlin J, Brown G, et al
    Management of Locally Advanced Rectal Cancer: ASCO Guideline.
    J Clin Oncol. 2024;42:3355-3375.
    >> Share

  52. XIA F, Wang Y, Wang H, Shen L, et al
    Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).
    J Clin Oncol. 2024;42:3308-3318.
    >> Share

    September 2024
  53. CHIBAUDEL B, Raeisi M, Cohen R, Yothers G, et al
    Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.
    J Clin Oncol. 2024 Sep 4:JCO2400394. doi: 10.1200/JCO.24.00394.
    >> Share

    August 2024
  54. LU J, Xing J, Zang L, Zhang C, et al
    Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial.
    J Clin Oncol. 2024 Aug 27:JCO2400393. doi: 10.1200/JCO.24.00393.
    >> Share

  55. TAKASHIMA A, Hamaguchi T, Mizusawa J, Nagashima F, et al
    Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
    J Clin Oncol. 2024 Aug 26:JCO2302722. doi: 10.1200/JCO.23.02722.
    >> Share

    July 2024
  56. WILLIAMS CJM, Gray R, Hills RK, Shires M, et al
    Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.
    J Clin Oncol. 2024 Jul 31:JCO2302030. doi: 10.1200/JCO.23.02030.
    >> Share

  57. SARTORE-BIANCHI A, Marsoni S, Amatu A, Torri V, et al
    How to Test HER2 for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405.
    J Clin Oncol. 2024 Jul 30:JCO2400805. doi: 10.1200/JCO.24.00805.
    >> Share

  58. PENG C, Kircher SM
    Neoadjuvant Chemotherapy in Colon Cancer: More Than Just an Optical Illusion.
    J Clin Oncol. 2024 Jul 25:JCO2400220. doi: 10.1200/JCO.24.00220.
    >> Share

  59. QIU YY, Yang S, Sun MQ, Huang JH, et al
    Age May Be an Important Factor Affecting Neoadjuvant Chemotherapy in Patients With Locally Advanced Colon Cancer.
    J Clin Oncol. 2024 Jul 24:JCO2400883. doi: 10.1200/JCO.24.00883.
    >> Share

  60. KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al
    Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis.
    J Clin Oncol. 2024;42:2506-2515.
    >> Share

  61. CHLEBOWSKI RT, Aragaki AK, Pan K, Luo J, et al
    Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial.
    J Clin Oncol. 2024 Jul 19:JCO2302092. doi: 10.1200/JCO.23.02092.
    >> Share

  62. JAIN A, Lau NS
    Liver Transplantation in Colorectal Cancer With Unresectable Liver Metastases: Disease Biology Cannot Be Ignored.
    J Clin Oncol. 2024 Jul 8:JCO2400619. doi: 10.1200/JCO.24.00619.
    >> Share

    June 2024
  63. NOWAK JA, Twombly T, Ma C, Shi Q, et al
    Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Clin Oncol. 2024 Jun 18:JCO2301680. doi: 10.1200/JCO.23.01680.
    >> Share

  64. ANTONIOTTI C, Rossini D, Pietrantonio F, Salvatore L, et al
    Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
    J Clin Oncol. 2024 Jun 12:JCO2302728. doi: 10.1200/JCO.23.02728.
    >> Share

  65. KAWAZOE A, Xu RH, Garcia-Alfonso P, Passhak M, et al
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736.
    >> Share

  66. BUTT J, Epplein M
    Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers.
    J Clin Oncol. 2024;42:1865-1867.
    >> Share

    May 2024

  67. Erratum: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial.
    J Clin Oncol. 2024 May 22:JCO2400997. doi: 10.1200/JCO.24.00997.
    >> Share

    April 2024

  68. Erratum: Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study.
    J Clin Oncol. 2024 Apr 30:JCO2400763. doi: 10.1200/JCO.24.00763.
    >> Share

  69. HU H, Zhang J, Li Y, Wang X, et al
    Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
    J Clin Oncol. 2024 Apr 2:JCO2301889. doi: 10.1200/JCO.23.01889.
    >> Share

  70. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.
    >> Share

    March 2024
  71. GALLOIS C, Shi Q, Pederson LD, Andre T, et al
    Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
    J Clin Oncol. 2024 Mar 28:JCO2301326. doi: 10.1200/JCO.23.01326.
    >> Share

  72. GAO Z, Zhu Z, Li K
    Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
    J Clin Oncol. 2024;42:1088.
    >> Share

  73. MEHTSUN WT, Gupta S
    Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer-We Must Do Better.
    J Clin Oncol. 2024 Mar 15:JCO2302186. doi: 10.1200/JCO.23.02186.
    >> Share

  74. DOMINGO E, Kelly C, Hay J, Sansom O, et al
    Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
    J Clin Oncol. 2024 Mar 14:JCO2301648. doi: 10.1200/JCO.23.01648.
    >> Share

  75. LORIA A, Ramsdale EE, Aquina CT, Cupertino P, et al
    From Clinical Trials to Practice: Anticipating and Overcoming Challenges in Implementing Watch-and-Wait for Rectal Cancer.
    J Clin Oncol. 2024;42:876-880.
    >> Share

  76. FOKAS E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, et al
    Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited.
    J Clin Oncol. 2024;42:872-875.
    >> Share

  77. BATTAGLIN F, Ou FS, Qu X, Hochster HS, et al
    HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
    J Clin Oncol. 2024 Mar 8:JCO2301507. doi: 10.1200/JCO.23.01507.
    >> Share

  78. SHAH SC, Camargo MC, Lamm M, Bustamante R, et al
    Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort.
    J Clin Oncol. 2024 Mar 1:JCO2300703. doi: 10.1200/JCO.23.00703.
    >> Share

    February 2024
  79. RAHBARI NN, Biondo S, Frago R, Feisst M, et al
    Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
    J Clin Oncol. 2024 Feb 27:JCO2301540. doi: 10.1200/JCO.23.01540.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016